Skip to main content
Transparency data

November 2026 BSTG meeting notes

Published 12 November 2026

The UK National Screening Committee (UK NSC) Blood Spot Task Group (BSTG) met on 9 November 2026.

The group received updates from the Warwick-Birmingham Screening Evidence Synthesis Group (WeBS-ESG) on the following projects:

  • evaluation of test accuracy studies in newborn blood spot (NBS) screening and rare disease settings
  • the strengths and limitations of methods and mechanisms for evaluating the benefits and harms of NBS screening
  • development of a position statement on the evaluation of whole genome sequencing and possible expansion of NBS screening

BSTG members provided valuable feedback on all the above workstreams and their input will be considered before the project papers are refined, signed off by the UK NSC and published.

Evaluation of test accuracy studies in newborn and rare disease settings

A member of the WeBS-ESG updated the group on the project exploring how best to assess test accuracy, which included 4 outputs:

  1. Review of more than 300 published studies on NBS screening test accuracy.
  2. Conceptual framework for the development and evaluation of tests and testing strategies for NBS screening.
  3. UK NSC position statement on principles for generating and interpreting test accuracy evidence in NBS screening.
  4. Options for future work.

The overall goal of the project is to help ensure decisions about starting or changing screening programmes are based on the most reliable evidence of how well tests work.

WeBS-ESG explained that the review of published studies, the development of a conceptual framework, and expert stakeholder discussions have all informed output number 3: the drafting of the UK NSC position statement.

Another member of WeBS-ESG then presented the draft position statement and its 6 principles, which broadly state that:

  • test accuracy evaluation should be appropriate to the phase of test development
  • methods should reflect the evaluation question and practical constraints
  • methodological compromises should be reported explicitly
  • evaluation should recognise the distinctive characteristics of screen-detected disease
  • methods for identifying and confirming the disease should be tailored to newborn screening
  • evaluation should cover the complete screening strategy rather than individual tests in isolation

BSTG members thanked WeBS-ESG and provided detailed comments on the position statement principles for WeBS-ESG to incorporate before it is finalised and published.

Evaluating the benefits and harms of newborn blood spot screening

A member of WeBS-ESG updated BSTG members on the project to help guide the UK NSC on the strengths and limitations of methods and mechanisms for evaluating the benefits and harms of NBS screening.

A review of current approaches identified 60 studies that evaluated the benefits and harms of NBS screening. Of these, 54 examined benefits and only 6 examined harms. The project has also looked at what other methods could be used for this purpose based on relevant literature and expert consultation.

This work has informed the drafting of UK NSC guidance on the merits and limitations of methods and mechanisms for evaluating NBS screening outcomes. BSTG members thanked WeBS-ESG and provided detailed feedback on both the review and the guidance.

Position statement on the evaluation of whole genome sequencing and the expansion of NBS screening

A member of WeBS-ESG summarised the work in progress to draft a UK NSC position statement on evaluating the expansion of newborn screening.

This statement aims to set out how the UK NSC would approach potential future large-scale evaluations of whole genome sequencing or the addition of multiple rare conditions to the NBS screening programme.

Feedback from BSTG members stressed the need to balance robust comparative evidence against ethical and equity concerns, and to evaluate not simply the harms, such as false positives and overdiagnosis, but also to set out how those harms might be mitigated.

Following their input, the position statement will be refined before being taken to the UK NSC for sign-off and publication.